SAN DIEGO, Sept. 27, 2016 /PRNewswire/ -- Histogen, Inc., a regenerative medicine company developing innovative products from cells grown under simulated embryonic conditions, today announced a license agreement with Pineworld Capital, Ltd., for the development and commercialization of its proprietary Hair Stimulating Complex (HSC) in Mainland China. Pineworld Capital is an affiliate of China-based, publicly traded Huapont Life Sciences, which has a $3 billion market capitalization.
Through an exclusive license and supply agreement, Pineworld will focus on clinical development, registration, marketing and sales of the HSC injectable hair growth treatment in China. Under the terms of the license, Histogen will receive milestone payments, a transfer price on the product, and escalating royalties on future sales. Histogen will utilize its patented technology process to manufacture HSC for the China market.
"We are honored to align with Huapont Life Sciences to bring HSC into China," said Dr. Gail Naughton, Histogen CEO and Chairman of the Board. "With its strong dermatology portfolio, Huapoint is an ideal partner for developing and commercializing Histogen's unique hair growth product to the world's most populous nation. Hair loss affects men and women around the world, and our goal is to find the best partners in each region to bring solutions to this global problem."
HSC is an injection treatment that has shown excellent safety and statistically and cosmetically significant hair growth in two Company-sponsored and one investigator-initiated clinical trial. Through Histogen's technology process, which mimics the embryonic environment including conditions of low oxygen and suspension, cells are triggered to become multipotent, and naturally produce proteins that are key in hair formation and the stimulation of hair follicles.
"Huapont Life Sciences is excited to partner with Histogen to bring its innovative product to the millions of men and women in China suffering from hair loss," said Hayden Zhang, Head of Investments for Huapont and CEO of Pineworld Capital. "By working closely together, we are confident HSC will enjoy tremendous market success."
Histogen is a regenerative medicine company developing innovative products from cells grown under simulated embryonic conditions, including low oxygen and suspension. Through this unique technology process, newborn cells are directed to naturally produce vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen's technology focuses on stimulating a patient's own stem cells by delivering a proprietary complex of multipotent human proteins that have been shown to support stem cell growth and differentiation. For more information, please visit www.histogen.com.
About Huapont Life Sciences
Huapont Life Sciences is a China-based company focused on the research and development of new and innovative healthcare products, and the manufacture, marketing and sale of leading pharmaceutical products, active pharmaceutical ingredients (known as APIs) and a portfolio of safe and effective agricultural herbicides (including NC16, NC34, NC36, NC125, NC201) serving the agricultural business throughout the US and South American markets. Huapont Life Sciences' pharmaceutical business includes dermatology products, cardiovascular products, anti-tuberculosis agents, autoimmune-related products and oncology-related products. Huapont Life Sciences' API business involves the production and sale of bulk pharmaceutical chemicals, pharmaceutical intermediates and preparations of Western medicines, with current annual revenues of approximately US $1.1 billion, and approximately 7,100 employees operating throughout Mainland China. Huapont Life Sciences is listed on the Shenzhen Stock Exchange (002004.SZ) and carries a current market capitalization of approximately US $3.0 billion.
SOURCE Histogen, Inc.